Kumar Sunny, Basu Malini, Ghosh Pratyasha, Pal Uttam, Ghosh Mrinal K
Cancer Biology and Inflammatory Disorder Division, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology (CSIR-IICB), TRUE Campus, CN-6, Sector-V, Salt Lake, Kolkata-700091 & 4, Raja S.C. Mullick Road, Jadavpur, Kolkata 700032, India.
Department of Microbiology, Dhruba Chand Halder College, Dakshin Barasat, West Bengal 743372, India.
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the complicated disease COVID-19. Clinicians are continuously facing huge problems in the treatment of patients, as COVID-19-specific drugs are not available, hence the principle of drug repurposing serves as a one-and-only hope. Globally, the repurposing of many drugs is underway; few of them are already approved by the regulatory bodies for their clinical use and most of them are in different phases of clinical trials. Here in this review, our main aim is to discuss in detail the up-to-date information on the target-based pharmacological classification of repurposed drugs, the potential mechanism of actions, and the current clinical trial status of various drugs which are under repurposing since early 2020. At last, we briefly proposed the probable pharmacological and therapeutic drug targets that may be preferred as a futuristic drug discovery approach in the development of effective medicines.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发了复杂的疾病COVID-19。由于缺乏针对COVID-19的特效药物,临床医生在治疗患者时持续面临巨大难题,因此药物重新利用原则成为了唯一的希望。在全球范围内,许多药物的重新利用工作正在进行;其中少数药物已获监管机构批准用于临床,而大多数药物正处于不同阶段的临床试验中。在本综述中,我们的主要目的是详细讨论自2020年初以来各种正在重新利用的药物基于靶点的药理学分类、潜在作用机制以及当前临床试验状况的最新信息。最后,我们简要提出了可能作为未来有效药物开发中药物发现方法的首选药理学和治疗药物靶点。